Drug Type Small molecule drug |
Synonyms Compound Bupivacaine Hydrochloride, Lidocaine Hydrochloride/Bupivacaine Hydrochloride, 盐酸利多卡因/盐酸布比卡因 + [1] |
Target |
Mechanism SCNA blockers(Sodium channel alpha subunit blockers), Sodium channels blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (23 May 2003), |
Regulation- |
Molecular FormulaC14H23ClN2O |
InChIKeyIYBQHJMYDGVZRY-UHFFFAOYSA-N |
CAS Registry73-78-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | CN | 31 May 2009 |
Phase 3 | 75 | (1% Lidocaine) | ululqhsyyv(dfzztgaknp) = tvsrdvmwla oencynhpin (lyxfuqiyvr, rwtpqesvem - ccsniisphx) View more | - | 31 Aug 2020 | ||
(0.25% Bupivacaine) | ululqhsyyv(dfzztgaknp) = tavsdarjhj oencynhpin (lyxfuqiyvr, qkxhjaqqbf - rnickyxdfg) View more | ||||||
Not Applicable | 14 | blzvjepqyn(nnsztmvjzs) = dhlxvkvspu bmpnrcpjxn (dmacscuxhj, hsijvbsgsu - sqqvykdmkf) View more | - | 06 Dec 2019 |